Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 7, 2013, Pages 835-843

  Cree, Bruce A C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Disease modifying therapies; fertility; lactation; multiple sclerosis; pregnancy

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CLADRIBINE; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; TERIFLUNOMIDE;

BONE MALFORMATION; CARDIOVASCULAR DISEASE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFORMATION; DRUG MANUFACTURE; DRUG SAFETY; EMBRYOTOXICITY; FETUS WASTAGE; HUMAN; HYDROCEPHALUS; LIVE BIRTH; LOW BIRTH WEIGHT; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY OUTCOME; PREMATURITY; PRENATAL EXPOSURE; REVIEW; SIDE EFFECT; SPONTANEOUS ABORTION; STILLBIRTH; TERATOGENICITY;

EID: 84878377092     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512471880     Document Type: Review

References (57)

1. Scialli AR, Buelke-Sam JL, Chambers CD, et al. Communicating risks during pregnancy: A workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res A Clin Mol Terato. 2004 ; 70: 7-12
2. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Federal Register 73: 04 (29May2008): pp.30831-30868, www.gpo.gov/fdsys/pkg/FR-2008-05-29/content- detail.html (accessed 27 January 2012).
3. Ferrero S, Pretta S, Ragni N. Multiple sclerosis: Management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2004 ; 115: 3-9
4. Boskovic R, Wide R, Wolpin J, et al. The reproductive effects of beta interferon therapy in pregnancy: A longitudinal cohort. Neurology. 2005 ; 65: 807-811
5. Sandberg-Wollheim M, Frank D, Goodwin TM, et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology. 2005 ; 65: 802-806
6. Sandberg-Wollheim M, Alteri E, Moraga MS, et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler. 2011 ; 17: 423-430
7. Coyle PK, Roberts S, Scheuerle A, et al. The Betaseron (Interferon Beta-1b) Pregnancy Registry. Int J MS Care. 2010 ; 12: S26
8. Foulds P, Richman S, Glick G, et al. Pregnancy outcomes from the Avonex® (interferon beta-1a) pregnancy exposure registry. Mult Scler. 2010 ; 16: P894
9. Rebif® Pregnancy Registry - Study Results - ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/results/NCT00338741 (accessed 27 January 2012).
10. Coyle P, Johnson K, Pardo L, et al. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone®). Neurology. 2003 ; 60: A60
11. Briggs GG, Freeman RK, Yaffe SJ Drugs in pregnancy and lactation: A reference guide to fetal and neonatal Risk. 9 th ed.Philadelphia, PA: Lippincott, Williams & Wilkins, 2011, pp.1-1, 728. Philadelphia, PA: Lippincott, Williams & Wilkins ; 2011: 1 728-1.
12. Biogen Idec Inc. Tysabri (natalizumab) prescribing information. http://www.tysabri.com/pdfs/I61061-13-PI.pdf (2012, accessed 20 March 2012).
13. Wehner NG, Skov M, Shopp G, et al. Effects of natalizumab, an α4 integrin inhibitor, on fertility in male and female guinea pigs. Birth Defects Res B Dev Reprod Toxicol. 2009 ; 86: 108-116
14. Wehner NG, Shopp G, Oneda S, et al. Embryo/fetal development in monkeys exposed to natalizumab, an α4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009 ; 86: 117-130
15. Biogen Idec Inc. Natalizumab NDA 2004, Pharmacological Review Part 3: 81-97. http://www/accessdat.fda.gov.drugsatfda-docs/nda/2004/125104s000- Natalizumab-Medr-P3.pdf (accessed 27 January 2012).
16. Mahadevan U, Nazareth M, Cristiano L, et al. Natalizumab use during pregnancy. Am J Gastroenterolo. 2008 ; 103: A1150
17. Hoevenaren IA, de Vries LC, Rijnders RJP, et al. Delivery of healthy babies after natalizumab use for multiple sclerosis: A report of two cases. Acta Neurol Scand. 2011 ; 123: 430-433
18. Cristiano L, Bozic C, Bloomgren G. Preliminary evaluation of pregnancy outcomes from the Tysabri® (natalizumab) Pregnancy Registry. Mult Scler. 2012 ; 18: P275
19. Cocco E, Sardu C, Gallo P, et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: The FEMIMS study. Mult Scler. 2008 ; 14: 1225-1233
20. Immunex Corporation. Novantrone New Drug Application Pharmacology Review Part 2. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2000/21120.pdf- Novantrone-Pharmr-P2.pdf (accessed 30 January 2012).
21. Immunex Corporation. Novantrone (mitoxantrone HCL) Briefing Document for the Peripheral & Central Nervous System Advisory Committee Meeting 16 December 1999. http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3582b1l.pdf (accessed 25 January 2012).
22. EMD Serono Inc. Novantrone (mitoxantrone) prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/019297s033s034lbl.pdf (2010, accessed 25 January 2012).
23. Novartis Pharmaceutical Corporation. Gilenya (fingolimod) prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf (2012, accessed 20 March 2012).
24. Novartis Pharmaceutical Corporation. Gilenya (fingolimod) capsules pharmacology review PDF. Submission date Dec 21, 2009. http://www.accessdata. fda.gov/drugsatfda-docs/nda/2010/022527Orig1s000TOC.pharmar.pdf (accessed 2 January 2012).
25. Novartis Pharmaceutical Corporation. Fingolimod. Summary of Product Characteristics.http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002202/WC500104528.pdf (accessed 2 January 2012).
26. Novartis Pharmaceutical Corporation, FTY720D Briefing Document for the Peripheral and Central Nervous System Drugs Advisory Committee Meeting 10 June 2010. http://www.fda.gov/downloads/AdvisoryCommittees/Materials/Drugs/ PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM214675.pdf (2010, accessed 2 January 2012).
27. Collins W, Francis G, Koren G, et al. Lack of interaction between fingolimod (FTY720) and oral contraceptives, and pregnancy experience in the clinical program of fingolimod in multiple sclerosis. Presented at The 63rd annual meeting of the American Academy of Neurology ; Honolulu, Hawaii ;..
28. Roll A, Reich K, Böer A. Use of fumaric acid esters in psoriasis. Indian J Dermatol Venereol Leprol. 2007 ; 73: 133-137
29. Biogen Idec. Fumaderm®, initial/Fumaderm®(dimethyl fumarate and ethyl hydrogen fumarate) prescribing information. http://www.psoriasis-support. de/media/ms/on/gebrauchsinfo-fumaderm-initial-070228. pdf (accessed 12 November 2012).
30. Dimethyl fumarate - National Library of Medicine - Hazardous substances data bank. Toxnet.nlm.nih.gov (accessed 12 January 2012).
31. FAO/WHO Expert Committee on Food Additives Series 6 (1975)http://www. inchem.org/documents/jecfa/jecmono/v06je04.htm (accessed 12 January 2012).
32. Wei Q, Runrong G, Xiangdong S, et al. Studies on teratogenicity of dimethyl fumarate. J Hyg Res. 1990 ; 19: 28-31
33. Peters P, Schaefer C Drugs during pregnancy and lactation treatment options and risk assessment. 2 nd ed.London, UK: Academic Press, 2007, p.456. Schaefer C Peters P Miller R, ed. London, UK: Academic Press ; 2007: 456.
34. Genzyme Corporation, a Sanofi company. Aubagio (teriflunomide) prescribing information. http://products.sanofi.us/aubagio/aubagio.pdf (2012, accessed 7 October 2012).
35. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 ; 365: 1293-1303
36. Kieseier B, Mednikova Z, Trabelsi N, et al. Pregnancy outcomes from teriflunomide treatment: Retrospective analysis of a global pharmacovigilance database. Mult Scler. 2011 ; 17: P472
37. BjörkAJönssonSFexT. Quinoline derivatives. Patent 6593343, USA, 2002.
38. Vukanovic J, Passaniti A, Hirata T, et al. Antiangiogenic effects of quinoline-3-carboxamide linomide. Cancer Res. 1993 ; 53: 1833-1837
39. Mazue G. Extrapolation to humans of animal studies: The experience of industry. Teratology. 1996 ; 53: 1A - 39A
40. Thöne J, Gold R. Laquinimod: A promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Drug Metab Toxicol. 2011 ; 7: 365-370
41. Ortho Biotech. Leustatin (cladribine injection) prescribing information. http://www.janssenbiotech.com/assets/Leustatin-PI.pdf (2007, accessed 2 January 2012).
42. TGA Health Safety Regulation. Australian Public Assessment Report of Cladribine Tablets, July2011. http://www.tga.gov.au/pdf/auspar/auspar-movectro. pdf (2011, accessed 2 January 2012).
43. Leustatin Product Monograph, http://www.yaofang.us/upload/product/ 201091219522532.pdf (2006, accessed 2 January 2012).
44. Cook S, Vermersch P, Comi G, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: The CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler. 2011 ; 17: 578-593
45. Orlowski RZ. Successful pregnancy after cladribine therapy for hairy cell leukemia. Leuk Lymphoma. 2004 ; 45: 187-188
46. Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012 ; 2012: 985646
47. Genzyme Corporation. Campath (alemtuzumab) prescribing information. http://www.campath.com/pdfs/2009-08-Campath%20US%20PI.pdf (2009, accessed 24 January 2012).
48. Hale G. CD52 (CAMPATH1). J Biol Regul Homeost Agents. 2001 ; 15: 386-391
49. Cada DJ, Levien T, Baker DE. Alemtuzumab. Hosp Pharm. 2001 ; 36: 962-972
50. Genentech Inc. Rituxan (rituximab) prescribing information. http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf (2012, accessed 24 January 2012).
51. Vaidyanathan A, McKeever K, Anand B, et al. Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys. Toxicol Sci. 2011 ; 119: 116-125
52. Chakravarty EF, Murray ER, Kelman A, et al. Pregnancy outcomes following maternal exposure to rituximab. Blood. 2011 ; 117: 1499-1506
53. Klink DT, van Elburg RM, Schreurs MWJ, et al. Rituximab administration in third trimester pregnancy suppresses neonatal B-cell development. Clin Dev Immunol. 2008 ; 2008: 271363
54. GlaxoSmithKline. Arzerra (ofatumumab) summary of product characteristics. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/ drugs/oncologicdrugsadvisorycommittee/ucm163891.pdf (accessed 2 January 2011).
55. GlaxoSmithKline. Arzerra (ofatumumab) prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125326lbl.pdf (2009, accessed 2 January 2012).
56. Roche. Zenapax (daclizumab) prescribing information. www.gene.com/gene/ products/information/zenapax/pdf/pi.pdf (2005, accessed 13 February 2012).
57. Roche. Daclizumab. Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000198/WC500057604.pdf (accessed 2 January 2012).